EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Expert Opinion on Pharmacological Treatment of Diabetic Peripheral Arterial Disease: Clinical Utility of Cilostazol/Ginkgo biloba Extract Combination (Renexin®)

Hwi Seung Kim, Won Jun Kim, Chang Hoon Lee, Hyunmin Ko, Jun Hwa Hong, Seon Mee Kang, Ah Reum Khang, Soo Kyoung Kim, Sang Joon Park, Yeoree Yang, Tae Jung Oh, Jeehee Yoon und 10 weitere

The Journal of Korean Diabetes · 30.06.2026 · 27 (2) · 56-64

DOI: 10.4093/jkd.2026.27.2.56 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Korean Diabetes, erschienen am 30.06.2026. Verfasst von Hwi Seung Kim und 21 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripheral arterial disease (PAD) is a macrovascular complication of diabetes mellitus associated with a high risk of cardiovascular events, lower-extremity amputation, and impaired quality of life. Cilostazol, a phosphodiesterase-3 (PDE3) inhibitor, is recommended as a first-line pharmacological agent for symptomatic PAD based on evidence that it helps improve walking distance and potentially stabilizes plaques, partly mediated by favorable effects on triglycerides and high-density lipoprotein cholesterol. Ginkgo biloba extract improves hemorheological parameters, including plasma viscosity and hematocrit, and may increase ankle-brachial index in patients with type 2 diabetes mellitus. Also, when used in combination therapy, cilostazol attenuates carotid intima-media thickness progression. However, high-quality evidence for G. biloba extract in diabetic PAD remains limited. Based on a comprehensive review of available clinical evidence and expert consensus, this expert opinion recommends G. biloba extract combination with cilostazol (Renexin®) as a second-line agent or adjunctive therapy primarily for symptom control—particularly the improvement of maximal walking distance—in patients with diabetic PAD who experience insufficient symptom control or intolerance to cilostazol monotherapy. This expert opinion also emphasizes individualized patient selection, careful screening for contraindications, and regular clinical monitoring, and urges large-scale randomized controlled trials in Korean patients with PAD to further establish a greater evidence base for pharmacological treatment.

Zitieren

APA

Kim, H. S., Kim, W. J., Lee, C. H., Ko, H., Hong, J. H., Kang, S. M., Khang, A. R., Kim, S. K., Park, S. J., Yang, Y., Oh, T. J., Yoon, J., Lee, J. H., Jeong, J. W., Cho, H., Choi, D., Kim, H. Y., Lee, J., Kim, S. Y., …, & Kim, C. H. (2026). Expert Opinion on Pharmacological Treatment of Diabetic Peripheral Arterial Disease: Clinical Utility of Cilostazol/Ginkgo biloba Extract Combination (Renexin®). The Journal of Korean Diabetes, 27(2), 56-64. https://doi.org/10.4093/jkd.2026.27.2.56

Vancouver

Kim HS, Kim WJ, Lee CH, Ko H, Hong JH, Kang SM, et al. Expert Opinion on Pharmacological Treatment of Diabetic Peripheral Arterial Disease: Clinical Utility of Cilostazol/Ginkgo biloba Extract Combination (Renexin®). The Journal of Korean Diabetes. 2026;27(2):56-64. doi:10.4093/jkd.2026.27.2.56

BibTeX
@article{Kim2026,
  author = {Kim, Hwi Seung and Kim, Won Jun and Lee, Chang Hoon and Ko, Hyunmin and Hong, Jun Hwa and Kang, Seon Mee and Khang, Ah Reum and Kim, Soo Kyoung and Park, Sang Joon and Yang, Yeoree and Oh, Tae Jung and Yoon, Jeehee and Lee, Ju Hee and Jeong, Jin Woo and Cho, Hochan and Choi, Dughyun and Kim, Hwa Young and Lee, Jung-Hwa and Kim, Sun Young and Lee, Ji-Hyun and Ju, Dal Lae and Kim, Chong Hwa},
  title = {Expert Opinion on Pharmacological Treatment of Diabetic Peripheral Arterial Disease: Clinical Utility of Cilostazol/Ginkgo biloba Extract Combination (Renexin®)},
  journal = {The Journal of Korean Diabetes},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {56--64},
  doi = {10.4093/jkd.2026.27.2.56}
}
Kostenlos starten →